The recent surge in leucovorin prescriptions for children with autism spectrum disorder (ASD) following high-profile endorsements by President Donald Trump and Robert F. Kennedy Jr. has sparked both interest and concern. While some families have embraced the treatment, others are skeptical, given the limited evidence supporting its effectiveness. This article delves into the story behind the 'Trump bump' in leucovorin prescriptions, the role of media and public statements, and the ongoing debate surrounding the drug's efficacy in treating autism.
The Trump Bump and Media Influence
The story begins in September 2025 when Trump and Kennedy Jr. made headlines by suggesting a link between acetaminophen (Tylenol) and autism risk during pregnancy. Amidst the controversy, leucovorin, a form of folate, emerged as a potential treatment for autism. Kennedy Jr. claimed it could benefit a significant number of children with ASD, while former FDA Commissioner Marty Makary suggested it could help hundreds of thousands or even up to 50% of kids with autism.
The UCSD study, led by Joshua Rothman, analyzed prescription trends of leucovorin among children with autism. The results revealed a dramatic increase in prescriptions following the Fox News report and the Trump announcement. The prescription rate surged from around 34 per 100,000 outpatient visits in 2023-2024 to 835 per 100,000 visits by November 2025, a 2,000% increase.
This surge in interest highlights the power of media and public statements in shaping healthcare trends. However, it also underscores the need for caution, as the lack of strong evidence supporting leucovorin's effectiveness for autism remains a concern.
A Drug Without Strong Data
The Trump administration's initial enthusiasm for leucovorin has since cooled. The FDA approved the expanded use of leucovorin to treat cerebral folate deficiency but explicitly declined to endorse it as an autism treatment due to the lack of robust evidence. This decision reflects the ongoing debate surrounding the drug's efficacy in treating ASD.
The credibility of leucovorin as an autism treatment has been questioned, with recent studies finding evidence against the initial claims. A positive trial testing leucovorin supplements in children with autism was retracted due to data errors and concerns. The largest trial to date, involving 77 children, was one of only five trials, further highlighting the limited evidence supporting the drug's effectiveness.
The Way Forward
Despite the controversy, the UCSD study's findings emphasize the importance of continued research on leucovorin's potential benefits for children with ASD. As the number of prescriptions increases, there is a growing need for rigorous data to guide treatment decisions. Rothman and his team advocate for further research to assess the long-term outcomes of leucovorin use in autism, ensuring that families and clinicians have access to the necessary information to make informed choices.
In conclusion, the 'Trump bump' in leucovorin prescriptions highlights the complex interplay between media, public statements, and healthcare trends. While the drug's potential benefits remain uncertain, the story underscores the need for caution, evidence-based decision-making, and continued research to address the challenges faced by families and children with autism spectrum disorder.
